Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 10/20 | 0.57 |
| ▸ | ELOC | Q15369 | 3/20 | 0.57 |
| ▸ | ELOB | Q15370 | 3/20 | 0.57 |
| ▸ | CPT2 | P23786 | 1/20 | 0.43 |
| ▸ | CPT1A | P50416 | 1/20 | 0.43 |
| ▸ | CCR1 | P32246 | 8/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21697315 | 0.86 | CPT2 (0.52) | VHLELOCELOBCPT2CPT1A | |
| SCHEMBL21696488 | 0.86 | CCR1 (0.53) | VHLCPT2CPT1ACCR1ALDH1A1 | |
| SCHEMBL25768393 | 0.85 | VHL (0.58) | VHLELOCELOBCCR1 | |
| SCHEMBL25768374 | 0.85 | VHL (0.58) | VHLELOCELOBCCR1 | |
| SCHEMBL21697292 | 0.85 | VHL (0.76) | VHLELOCELOB | |
| SCHEMBL25769085 | 0.85 | VHL (0.76) | VHLELOCELOB | |
| SCHEMBL25768411 | 0.84 | VHL (0.42) | VHLELOCELOBCCR1 | |
| SCHEMBL25768343 | 0.84 | VHL (0.58) | VHLELOCELOBCCR1 | |
| SCHEMBL16277207 | 0.84 | CCR1 (0.57) | VHLCPT2CPT1ACCR1PKM | |
| SCHEMBL25768409 | 0.84 | VHL (0.59) | VHLELOCELOBCCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203030-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | ARVINAS OPERATIONS, INC. | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203030-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | VHL, MDM2, XIAP | VHL 1/4885ELOC 203/4885ELOB 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.